Topic Archives: CAR-T

Comments

  • Gr8Full!

    $JNJ, $GILD, #EDIT etc. - As gene editing explodes, a new report from Goldman says Chinese groups are seizing the lead o...

  • Avatar

    $SRNE I've been watching $SRNE since it was first mentioned here a few months ago, but have considered it overpriced ...

  • Gr8Full!

    $srne nice +7% move today, hoping to see this one head back to it's highs at $10+. Long, 1/2 position, cost average = $7...

  • Gr8Full!

    $SRNE ow - Sorrento Therapeutics Autologous Anti-CEA CAR-T Cell Therapy for Liver Metastases Demonstrates Therapeutic Ac...

  • Avatar

    $SRNE small position - Don't know anything about $BLCM, but Sorrento's CAR-T play has not yet been validated in actual t...

  • Avatar

    $SRNE Vs $BLCM both CAR-T stocks does anybody have an opinion why SRNE would be worth double the mkt cap especially cons...

  • Avatar

    just check out hep c; a few pills can cure it so they charge a few hundred thousand and make a mint, or the CAR-T cell t...

  • Avatar

    $AUPH OW a lot , Hi Mary, I took a starter position with SRNE today. Call this dumb luck, but i sold all my positions ...

  • Avatar

    Seeking Alpha does have a lot of good contributors, article writers and forum participants. Of course there are people w...

  • Avatar

    $SRNE long - news - Sorrento Therapeutics CAR-T Manufacturing Capacity Expanded With Opening of East Coast GMP Site in A...

  • Avatar

    $SRNE LONG Could Sorrento Therapeutics be the next minnow gobbled up in biotech feeding frenzy? Share 09:56 23 Ja...

  • Avatar

    SRNE-NP- company Doc talked fondly of yesterday and former shareholder. Lurking with this company with its leading antib...

  • Avatar

    $SRNE np I would never have been able to guess this one - having had and sold a small position before, and forgotten ...

  • Dr. KSS MD PhD

    OK, gather round all. I'm going to reveal one of the Christmas 12 here before the next column on that actually appears. ...

  • SoGiAm

    $XYZ plz $CELG np , $JUNO np - Celgene reportedly readies big bid for CAR-T player Juno https://endpts.com/wsj-jun...

  • Avatar

    $ATNM Cheers and thanks for those articles dhnida. I think you are correct on the individualized treatment for CAR-T but...

  • Avatar

    $ATNM long tyler_l45. So with CAR-T, it is antibody specific also. I am pasting from a cancer network website -"Ultim...

  • Avatar

    $ATNM Long. Thanks for your post dhnida. I am long in ATNM as well, have only been in it for about 10 months (since Marc...

  • Dr. KSS MD PhD

    Yesterday a caller asked about Fate Therapeutics $FATE. This is a San Diego cellular immunotherapies company working in ...

  • Dr. KSS MD PhD

    NEVER let Cramer influence your biotech investing decisions. He's an interesting and jolly man, but this is NOT his sect...

  • Dr. KSS MD PhD

    I've run that by two people I know "in the business" that I regard as qualified to guess. Even applying conservative met...

  • Dr. KSS MD PhD

    It's pending further study, but predicted to help at least to a degree. A good way to think about hyaluronic acid stroma...

  • Avatar

    $HALO How fortuitous as I wanted to ask you about Halozyme. Have been trying to follow the many posts that you and @f...

  • SoGiAm

    "By forming pericellular coats, HA can protect tumor cells from T cell attack-Several tumor cells produce ⬆️d amount...

  • Avatar

    $afmd I believe it is due to investor fear of the high bar being set by CAR-T stocks in AML and they will also need to r...

  • Avatar

    I dialed up on TWITTER .....ASH conference and it's all about CAR-T....

  • Avatar

    Some new data from: $AFMD : http://affimed.com/pdf/20171211_afmd_ash_afm13_afm26_posters_pr_final.pdf And $AAVXF ...

  • SoGiAm

    #ASH17 NEWS http://e.endpointsnews.com/t/ViewEmail/t/16F7237A4D7B4F15/2F80028A944F69C925D77A725F39070E The BCMA-targ...

  • SoGiAm

    #Moderation Please! $FATE long – Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8aß+ T Cells fro...

  • SoGiAm

    $FATE long - Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8aß+ T Cells from Clonal Engineered Ma...

  • SoGiAm

    #EndPoints In a blow to Eli Lilly, Novo Nordisk lands FDA OK for their next big entry in the diabetes market: Ozempic ...

  • Avatar

    We have 100 reasons to like (GILD) right now, which isn't a direct relation to the article above but if your looking to ...

  • Dr. KSS MD PhD

    The data here are excellent. Full completion of development of entinostat is supported. For reasons I don't get the stoc...

  • Dr. KSS MD PhD

    Agree, Daniel. I've not got a penny in this space. Crazy, in my view. And if you think these companies are going to ring...

  • Dr. KSS MD PhD

    Just a reminder: the biotech tide is out right now. Don't get uneasy at shriveled portfolio balances. We're in a season ...

  • Avatar

    Like this company Immune Design (IMDZ) at these levels and their immune methods look like the real deal and platform loo...

  • Dr. KSS MD PhD

    Here's a rather important study, NOT by Trillium, that definitely bulks up the case FOR what Trillium is doing. Have ...

  • Dr. KSS MD PhD

    I exitec $AFMD weeks back. It needs a new helm. I have to say I am outright livid at mgmt because they are fumbling the ...

  • SoGiAm

    $MRK & much more... NEW http://e.endpointsnews.com/t/ViewEmail/t/A537ED71EDB429B5/2F80028A944F69C925D77A725F39070E...

  • Avatar

    $CYAD np, AFMD long 1/2 p, Kite -long position closed. https://www.celyad.com/en/news/celyad-reports-a-first-complete...

  • Avatar

    $clrb in light of today's news if there is something i have never understood about clrb is the trading. I would think ...

  • Avatar

    $nano Hi pguathua, I've been following the "nano particle vector" with great iinteresr. Right now, the easiest ...

  • Avatar

    $ No ticker http://www.fiercebiotech.com/research/hit-and-run-gene-therapy-nanoparticles-could-enhance-car-t-treatments...

  • Avatar

    $GILD $KITE John Carroll's take on the buyout: UPDATED: Diving deep into CAR-T, Gilead forges $12B buyout deal for...

  • Dr. KSS MD PhD

    Well-played DBMD. There's just never been a question as I see it that $KITE was the best CAR-T house. And Gilead's choic...

  • SoGiAm

    $GILD has 20B left to spend. :-) Could this deal be the beginning of many M&A deals in #biotech? $GILD $KITE de...

  • Dr. KSS MD PhD

    Who knew? $GILD takes over $KITE. $GILD has long bemoaned the absence of deals that "make sense." How the heck does THIS...

  • Avatar

    Nice article on Dr. Carl June, one of the CAR T -cells pioneers. https://www.fredhutch.org/en/news/center-news/2017/08/...

  • Dr. KSS MD PhD

    Still long $AFMD with a half position; I've sold none. The pre-clinical and clinical programs are original, and as I und...

  • Avatar

    I work in the oncology sector and there are great breakthroughs especially in the CAR-T arena. I am invested in Kite Pha...

  • Dr. KSS MD PhD

    CAR-T would be ONLY for instances where the $APTO drugs fail. CAR-T will always be last resort,...

  • DBMD

    A personal thanks for KITE and BLUE. You talked me out of JUNO, and I moved to KITE with good prices. Sucking wind on so...

  • Dr. KSS MD PhD

    Hi hmaaita: I wondered similarly. The unanimous backing is not entirely a surprise in that NIH has a stake in CAR-T via ...

  • Avatar

    $AFMD Long FP I've been a silent memeber of SGS for a few months now and I really appreciate Dr KSS guidance and leade...

  • Avatar

    $NVS $CAR-T CTL019 #AML FDA advisers back Novartis’ game-changing personalized CAR-T for cancer, approval in sight ...

  • Avatar

    $CAR-T $KITE $NVS #Ethics A soul-searching article published on the eve of CAR-T's first approval "Sophie’s Choi...

  • Avatar

    $Kite: Kite Pharma, Inc., (Nasdaq: KITE), a leading cell therapy company, today announced that the United States Patent ...

  • Avatar

    Thank you, Dr. KSS, for excellent critique of this company and CAR-T...

  • Avatar

    Nov. 1, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) and Ospedale Pediatrico Bambino Gesù (OPBG), a leading Euro...

  • Avatar

    BLCM doesn't seem to have it's own cd19 trials. However, in 2016 it announced expanded collaboration with Ospedale Pedi...

  • Dr. KSS MD PhD

    Aileron is IPO'ing too and is an even hotter company in my estimation. It's a Cambridge, MA, company using "stapled pept...

  • Dr. KSS MD PhD

    I agree with Travis's excellent synopsis of this situation and this company. I was formerly long $BLCM, but this one has...

  • Avatar

    Could BMCA be the new target for CAR-T ? https://endpts.com/nanjing-legend-wows-asco-researchers-with-early-data-on-a-b...

  • Avatar

    Nice CAR-T blog report. https://smithonstocks.com/key-investment-considerations-relating-to-much-anticipated-car-t-prod...

  • Avatar

    CAR-T and Novartis - This is an interesting article from Endpoints: https://endpts.com/novartis-isnt-messing-around-wit...

  • Avatar

    Nice post Roger. If I may add a little color to the CAR-T space in general: Dr. Tripathy of MD Anderson recently summ...

  • Dr. KSS MD PhD

    No, not naive at all. Abi has agent 196, which is a liposomal formulation of a proprietary glycolipid shown to turn on i...

  • SoGiAm

    Very interesting! --> CAR-carrying nanoparticles reprograms immune cells to fight cancer https://www.fredhutch.org/e...

  • Avatar

    $BLCM NP but interested BLCM Bellicum Pharma announces two presentations of preclinical results on its proprietary du...

  • Avatar

    13:29 $SRNE Long Sorrento Therapeutics announces results from Phase Ib single arm trial testing its anti-CEA CAR-T in...

  • Dr. KSS MD PhD

    Geoff: I think maybe a better way to put it is that antibodies against these MHC peptides combos aren't so hard to raise...

  • Avatar

    KITE - np Kite scores a landmark win with promising 6-month lymphoma data for lead CAR-T http://tinyurl.com/gq9vww5...

  • Avatar

    CAR-T research - This is an article in Science Daily on February 14th concerning a research break through at Mayo Clinic...

  • Dr. KSS MD PhD

    Trade notification: $KITE full position liquidated this am Reasons: (1) to take profit (2) misgivings...

  • Avatar

    CLLS prepares with off shelf with CAR-T therapy. https://endpts.com/cellectis-preps-for-groundbreaking-us-trials-for-an...

  • Avatar

    $KITE, $BLCM, $JUNO, $NVS, $BLUE - CAR-T: And further to Dr. KSS' pending insight I share an article to wet our interes...

  • Dr. KSS MD PhD

    Alley: some weeks back you posted a question in the threads that was, in essence, "Whither CAR-T?" I didn't purposively ...

  • Avatar

    $STML: Excerpts of a Ladenburg report issued yesterday after the AF "hit" piece. HIGHLIGHTS: --Stemline reports one ...

  • Dr. KSS MD PhD

    Hi geoff: Caruso and I re-conversed at the end of his talk specifically about (1). I am expecting slightly less efficacy...

  • Avatar

    $CLRB (no position) I listened to the videotaped session. Impressive! I liked one quote: "An ATM of intellectual pr...

  • SoGiAm

    $CLLS long - ICYMI: Investigators detail some of the hopes – and fears – behind Cellectis’ off-the-shelf CAR-T $C...

  • SoGiAm

    Investigators detail some of the hopes – and fears – behind Cellectis’ off-the-shelf CAR-T $CLLS $KITE $JUNO $NVS...

  • Dr. KSS MD PhD

    $KITE will be first to FDA with BLA filing for CAR-T indication, but surprisingly Novartis is right on their heels: htt...

  • SoGiAm

    $CLLS long - PRESS RELEASE http://www.cellectis.com/en/content/four-prominent-physicians-join-cellectis-clinical-advi...

  • Avatar

    Hi Frenchy, sorry I don't have links on hand to offer you. My distinct impression is that $ZIOP is among the weakest of ...

  • Avatar

    Looks like FBIO has 4 Bio companies it owns with one being MustangBio. that had good results with its brain cancer drug ...

  • Avatar

    Mosley: $TGTX's core technologies have nothing to do with CAR-T cell therapy, although its main assets may be in combo s...

  • Avatar

    To All, Someone posted yesterday that Fortress Bio, symbol FBIO, had success with CAR T cell immunotherapy, is that si...

  • Avatar

    Anecdotal evidence m of FBIO (fortress bio) treatment using genetically modified Car-T immunotherapy (stock up pre-marke...

  • SoGiAm

    $KPTI np - CC STOMP Selinexor = KPT-330 focus was on #MM but broad application as XPL1 expressed in many cancers XPL1 ...

  • Avatar

    Novartis (NVS) in the hunt along with KITE for the first established CAR-T treatment to come to the market.It should be...

  • Avatar

    $KITE Kite Pharma Initiates Rolling Submission of U.S. Biologics License Application (BLA) for KTE-C19, its Investiga...

  • Avatar

    Yes will post as data becomes available.. I like the switch...This pioneering technology is triggered by rimiducid, a sm...

  • Avatar

    A highly informative analysis of BLUE's interim results from anti-BCMA study released today, with critical comments on t...

  • Avatar

    $KITE's CAR-T anti-CD19 therapy also employs fludarabine + cyclophosphamide, but only in small amounts. So far no casual...

  • SoGiAm

    $CLLS - Cellectis Announces Two Oral Presentations and One Poster at the 2016 ASH Annual Meeting November 7, 2016 –...

  • SoGiAm

    $CLLS long - Cellectis Announces Two Oral Presentations and One Poster at the 2016 ASH Annual Meeting November 7, ...

  • Dr. KSS MD PhD

    Hi: I feel there's a place for such a drug. Recall that Durham's Chimerix was trialling brincidofovir for CMV and ran in...

  • Avatar

    CAR T race is on. Once thought that Novartis was leader here to come first to the market but tend to believe KITE may be...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch